Literature DB >> 9721851

Rare loss-of-function mutation of a death receptor gene in head and neck cancer.

S I Pai1, G S Wu, N Ozören, L Wu, J Jen, D Sidransky, W S El-Deiry.   

Abstract

The chromosomal region 8p21 contains a number of putative tumor suppressor genes and is a frequent site of translocations in head and neck cancers. Recently, a novel tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor gene, KILLER/DR5, a member of the tumor necrosis factor receptor family, was identified as a potential mediator in p53-dependent apoptosis and mapped to 8p21 by fluorescence in situ hybridization. We have determined the genomic structure of KILLER/DR5 and performed sequence analysis of all 10 coding exons in 20 primary head and neck cancers with allelic loss of chromosome 8p. To screen for a subset of mutations localized to the functional cytoplasmic death domain, we sequenced this region in an additional 40 primary head and neck cancers. We found two alterations in this domain, including a 2-bp insertion at a minimal repeat site, introducing a premature stop codon and resulting in a truncated protein. This KILLER/DR5 mutation was also present in the germ line of the affected patient, and the tumor did not have a p53 mutation by sequence analysis. Transfection studies in head and neck squamous cell carcinoma and colon and ovarian carcinoma cell lines revealed loss of growth-suppressive function associated with the tumor-derived KILLER/DR5 truncation mutant. These observations provide the first evidence for mutation of a TRAIL death receptor gene in a human cancer, leading to loss of its apoptotic function.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9721851

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  31 in total

Review 1.  Resistance to TRAIL and how to surmount it.

Authors:  Danijela Maksimovic-Ivanic; Stanislava Stosic-Grujicic; Ferdinando Nicoletti; Sanja Mijatovic
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

2.  Distinct TRAIL resistance mechanisms can be overcome by proteasome inhibition but not generally by synergizing agents.

Authors:  Christina Menke; Lianghua Bin; Jacqueline Thorburn; Kian Behbakht; Heide L Ford; Andrew Thorburn
Journal:  Cancer Res       Date:  2011-03-01       Impact factor: 12.701

3.  Ubiquitin-specific protease 8 links the PTEN-Akt-AIP4 pathway to the control of FLIPS stability and TRAIL sensitivity in glioblastoma multiforme.

Authors:  Amith Panner; Courtney A Crane; Changjiang Weng; Alberto Feletti; Shanna Fang; Andrew T Parsa; Russell O Pieper
Journal:  Cancer Res       Date:  2010-05-18       Impact factor: 12.701

Review 4.  Programmed cell removal: a new obstacle in the road to developing cancer.

Authors:  Mark P Chao; Ravindra Majeti; Irving L Weissman
Journal:  Nat Rev Cancer       Date:  2011-12-08       Impact factor: 60.716

5.  RAD51C--a new human cancer susceptibility gene for sporadic squamous cell carcinoma of the head and neck (HNSCC).

Authors:  Kathrin Scheckenbach; Stephan E Baldus; Vera Balz; Marcel Freund; Petra Pakropa; Christoph Sproll; Karl-Ludwig Schäfer; Martin Wagenmann; Jörg Schipper; Helmut Hanenberg
Journal:  Oral Oncol       Date:  2013-12-06       Impact factor: 5.337

6.  mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells.

Authors:  Amith Panner; C David James; Mitchel S Berger; Russell O Pieper
Journal:  Mol Cell Biol       Date:  2005-10       Impact factor: 4.272

7.  Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells.

Authors:  Vassiliki Poulaki; Constantine S Mitsiades; Vassiliki Kotoula; Sophia Tseleni-Balafouta; Avi Ashkenazi; Demetrios A Koutras; Nicholas Mitsiades
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

8.  The small heat shock protein HspB2 is a novel anti-apoptotic protein that inhibits apical caspase activation in the extrinsic apoptotic pathway.

Authors:  Shayna E Oshita; Feng Chen; Toni Kwan; Fruma Yehiely; Vincent L Cryns
Journal:  Breast Cancer Res Treat       Date:  2010-01-20       Impact factor: 4.872

Review 9.  TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies.

Authors:  Peter A Holoch; Thomas S Griffith
Journal:  Eur J Pharmacol       Date:  2009-10-18       Impact factor: 4.432

10.  Targeting PP2A inhibits the growth of triple-negative breast cancer cells.

Authors:  Mohammed Hafiz Uddin; Julio M Pimentel; Madhumita Chatterjee; Joshu E Allen; Zhengping Zhuang; Gen Sheng Wu
Journal:  Cell Cycle       Date:  2020-02-03       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.